Fig. 5 | Scientific Reports

Fig. 5

From: Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer

Fig. 5

Pyrotinib enhances the antitumor effect of T-DM1 in vivo. (a) Images of JIMT-1 xenografts harvested after 21 days of treatment with T-DM1 (10 mg/kg) with or without pyrotinib (2 mg/kg) (n = 6). (b) Changes in tumor weight in the examined mice. (c) Changes in tumor volume in the examined mice. (d) Body weight changes in mice after treatments. (e) Representative images displaying HE and IHC staining of xenograft tumor tissues (×400), scale bars = 50 μm. The histogram shows the average absorbance of HER2. (f) The protein expression levels of HER2 and its downstream signaling pathways in tumor tissues of each group were analyzed by western blot. GAPDH served as the loading control. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = not significant. Results are representative of 3 independent replicates.

Back to article page